Assets

TCR Assets

TCR-based therapeutics demonstrate significant advantages and promising prospects. Compared to CAR-T, TCR-T cells can recognize intracellular antigens, exhibit superior infiltration into solid tumors, and show a lower incidence of cytokine release syndrome (CRS). TCR protein drugs further overcome the limitations of cell-based therapies, offering advantages such as lower costs, simpler production processes, and enhanced safety profiles, enabling the extension of TCR therapies to a wider range of therapeutic areas. In addition, soluble TCR can also be used in TCE therapies.

  • 9
    TCR ASSETS
  • 10+
    TCR-mimic ASSETS
  • 200+
    ANTIBOTY ASSET PARTNERSHIPS
related resource

on this page

  • Advantages of Biocytogen's TCR Platform
  • Biocytogen's TCR Assets Under Development

Webinars

View All

    Posters

    View All
      Advantages of Biocytogen's TCR Platform
      • The TCR molecules are derived from our proprietary RenTCR platform.
      • This platform enables the rapid acquisition of highly specific and reactive natural TCRs.
      • It significantly shortens the development cycle and reduces the cost of obtaining TCRs.
      • These advantages support the establishment of off-the-shelf TCR libraries.
      • Additionally, the platform can be used for novel epitope discovery and new target screening.
      Biocytogen's TCR Assets Under Development
      Target Type of antigen HLA Immunization Binding Assay In Vitro Function Verification Epitope Identification Specificity Verification In Vivo Function Evaluation Safety Evaluation
      MAGEA4/8 CTA HLA-A2.1
      PRAME CTA HLA-A2.1
      PRAME CTA HLA-A24.2
      NY-ESO-1 CTA HLA-A2.1
      MAGEA1 CTA HLA-A2.1
      MAGEA10 CTA HLA-A2.1
      KRAS G12V Neoantigen HLA-A11.1
      KRAS G12D Neoantigen HLA-A11.1
      HPV16 E7 Virus HLA-A2.1

      CTA: Cancer-testis Antigen